Illumina (ILMN) News Today

Illumina, Inc. (NASDAQ: ILMN) is trading higher after a cluster of upbeat catalysts reinforced investor confidence in its clinical sequencing growth story.

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, citing improving confidence in clinical sequencing momentum, consumables pricing, and the product pipeline. Quiver Quantitative article
• Positive Sentiment: Recent earnings and guidance updates showed Illumina beating Q1 expectations and lifting FY2026 outlook, which supports the view that execution is improving and growth is stabilizing. Zacks article
• Positive Sentiment: Illumina’s board authorized an additional $1.5 billion in share repurchases, a shareholder-friendly move that can help underpin the stock. Quiver Quantitative article
• Neutral Sentiment: There was also fresh insider selling, including additional share sales by director Keith Meister and a smaller sale by the chief accounting officer. While not necessarily tied to business performance, the activity may temper sentiment around the stock. SEC filing

Overall, ILMN appears to be rising on analyst optimism and continued confidence in its sequencing demand, pricing power, and higher 2026 guidance, outweighing concerns from insider selling.